ARIBIO Alzheimer Drug Data and Samsung XR News Lead Coverage

ARIBIO Holdings surged in news volume after Phase 3 Alzheimer's trial results, while Samsung Electronics' XR education feature and a wave of 5% ownership filings also drew heavy coverage.

Articles3,428▼13% vs Mon, Nov 16
DART filings198▼87% vs Mon, Nov 16
Companies634▼5% vs Mon, Nov 16
Most covered글로벌테크놀로지313 articles
At a glance
  • KOSPI 4,968.48 (-2.59%), KOSDAQ 650.06 (-2.34%) — fallout from a slump in U.S. chip stocks
  • Samsung Electronics -3.30%, SK hynix -1.96% — SK hynix closes at KRW 1,098,000
  • Sorux -29.86% amid AriBio dementia drug Phase 3 news, volume 10x normal
  • Hanmi Pharmaceutical +0.45% on early Phase 1 cancer data; Hyosung TNC -3.02% on bio-spandex
  • Ahead: SFC, Ucast subscriptions Nov. 18-19; Monetary Policy Committee Nov. 26

Indexes: Chip slump drags KOSPI below 5,000

The KOSPI fell 132.02 points (2.59%) on the 17th to 4,968.48 from 5,100.5 the previous day. The KOSDAQ dropped 2.34% to 650.06 from 665.65. Volume was 0.8x the 20-session average for the KOSPI and 0.99x for the KOSDAQ. The won/dollar rate was little changed, up 0.18%. Compared with a month ago, the KOSPI is 13.86% lower and the KOSDAQ 19.64% lower.

There were 3,417 stock-related news articles and 196 filings on the day, with 633 listed companies named in the coverage. Following a sharp drop in U.S. chip stocks, Samsung Electronics and SK hynix both fell, dragging the index lower. By catalyst type, earnings (214 articles) and clinical trials and approvals (126) were prominent, making pharma and biotech news stand out.

Indexes and FX
ItemCloseChange1-month
KOSPI4,968.48-2.59%-13.86%
KOSDAQ650.06-2.34%-19.64%
Won/dollarabout 1,336+0.18%+0.17%
ATS View take This decline looks more like a direct carryover from U.S. chip stocks than a reaction to domestic company-specific bad news. With volume below normal, it is hard to call it panic selling. But with the index now below a psychological threshold, whether U.S. chip stocks stabilize and the outcome of the Monetary Policy Committee meeting on Nov. 26 are the variables that will set the next direction.

Chips: Samsung Electronics and SK hynix fall together

Samsung Electronics KRW 190,300 (-3.30%)

Samsung Electronics fell 3.3% to KRW 190,300 from KRW 196,800, on volume of 16.77 million shares, 0.93x the average. An analysis showing Samsung Electronics' and SK hynix's China revenue quadrupled, and news that XR was added to its Galaxy AI experience program (covered by 44 outlets), failed to support the stock. Its one-month decline is 12.71%.

SK hynix KRW 1,098,000 (-1.96%)

SK hynix fell 1.96% from KRW 1,120,000, with reports noting it had dropped below KRW 1.1 million for the first time in seven months. Volume was 0.96x the average, and its one-month decline is 14.02%. Related articles fell to 65 from 116 the previous day.

ATS View take Both stocks fell on normal volume, which reads as joint weakness driven by overseas factors. There are earnings-side catalysts such as rising China revenue, but this is a phase in which market concern about U.S. AI chip investment weighs more heavily. Whether U.S. chip stocks rebound is the most direct checkpoint.

Pharma and biotech: Sorux plunges, Hanmi edges up

Sorux KRW 2,560 (-29.86%)

Sorux, grouped with AriBio in news coverage, fell 29.86% to KRW 2,560 from KRW 3,650, close to the daily limit-down. Volume was 16.74 million shares, 10.38x the average. AriBio said its oral Alzheimer's treatment slowed symptom progression by 31% in the monotherapy arm of a Phase 3 trial, but reports followed of a strong backlash after the announcement. Sorux-related articles numbered 55, nearly 29 times its usual daily average of 1.9.

ATS View take A related stock plunging despite an announcement that the trial met its goal suggests expectations were already priced in, or that the market took the details of the results conservatively. Stocks that price in expectations ahead of time are prone to sharp swings once the catalyst is spent. Volatility is likely to remain high until the U.S. filing schedule and disclosure of full data are confirmed.

Hanmi Pharmaceutical KRW 448,500 (+0.45%)

Hanmi Pharmaceutical said two next-generation cancer drug candidates showed early antitumor activity in global Phase 1 trials. Its obesity drug partnership with Eli Lilly also drew attention. The stock rose 0.45%, and its one-month return is 15.15%.

HK inno.N KRW 36,600 (+1.24%) · Daewoong Pharmaceutical KRW 100,100 (-0.60%)

HK inno.N rose 1.24% after K-CAB received product approval in Brazil, a market valued at KRW 1.1 trillion. Daewoong Pharmaceutical released interim Phase 1 results for an autoimmune drug candidate and fell 0.6%.

ATS View take The gains in Hanmi and HK inno.N in a falling market can be attributed to catalysts with confirmed progress, such as approvals or trial results. Early Phase 1 results are at an early stage of development, however, so the schedule for entering the next trial phase is the more important checkpoint.

Materials, construction and autos

Hyosung TNC KRW 289,500 (-3.02%)

Hyosung TNC said it will target the European textile market with bio-spandex made from sugarcane. The stock, which usually draws little coverage, was the subject of 41 articles. Its shares, however, fell 3.02% on volume of just 0.34x the average.

Korea Zinc KRW 815,000 (-4.90%)

Korea Zinc said it will enter the solar panel waste recycling market through a joint venture with U.S.-based SOLARCYCLE, but the stock fell 4.9%. There was also news that the government will resume overseas mineral investment.

Daewoo E&C KRW 10,600 (-4.42%) · Hyundai Motor KRW 259,000 (-2.45%)

Daewoo E&C fell 4.42% amid news of a collaboration on the Sinwol Siyoung reconstruction project, bringing its one-month decline to 29.1%. Hyundai Motor fell 2.45% amid reports of the union's demand for a retirement age extension and declining plant utilization. There was also news that Hyundai Motor and Hyundai Mobis will invest KRW 254.7 billion in Motional.

ATS View take Medium- to long-term catalysts such as eco-friendly materials or new business ventures struggle to draw a share price response in a market with this much index volatility. Declines on light volume read as a result of waning interest, and these catalysts may only be reassessed once the market stabilizes.

Share prices of the most-covered stocks

Most-covered stocks (closing prices)
CompanyCloseChangeVol vs 20-day avg1-month
HK inno.N36,600+1.24%1.21x+1.95%
Hanmi Pharmaceutical448,500+0.45%0.63x+15.15%
Amorepacific130,000+0.31%0.54x-6.14%
Industrial Bank of Korea19,160-0.21%0.67x-5.15%
KakaoBank21,050-0.71%0.76x+2.18%
NAVER170,000-1.68%0.64x-7.05%
GS E&C30,650-1.76%0.48x+6.24%
SK hynix1,098,000-1.96%0.96x-14.02%
Hyundai Motor259,000-2.45%0.57x-20.55%
Hyosung TNC289,500-3.02%0.34x+4.89%
Samsung Electronics190,300-3.30%0.93x-12.71%
Nongshim347,000-3.34%1.27x-15.67%
SK Innovation103,000-3.65%0.51x-36.81%
Daewoo E&C10,600-4.42%0.48x-29.10%
Korea Zinc815,000-4.90%0.81x-18.42%
Sorux2,560-29.86%10.38x-11.11%

Industrial Bank of Korea said it will supply KRW 75 billion in venture capital to innovative companies outside the Seoul metropolitan area and fell 0.21%. SK Innovation has lost 36.81% over the month, the steepest decline in the table. GS E&C fell 1.76% as it unveiled its vision for future housing, but its one-month return remains positive at 6.24%.

ATS View take The stocks that fell less in the downturn were in sectors such as finance and pharma, which are relatively less exposed to the economy and the chip cycle. In contrast, refining, chemical and construction stocks have one-month declines of around 30%, and the gap between sectors keeps widening.

Checklist ahead

  • Nov. 18: AL Robot listing — IPO price KRW 17,600, lock-up commitment ratio 1.1%
  • Nov. 18-19: SFC (IPO price KRW 31,600) and Ucast (KRW 19,000) subscriptions
  • Nov. 20: Hana Aerodynamics listing; one-month lock-up expiry at Elice Group (tradable float 20.77% → 32.71%)
  • Nov. 26: Bank of Korea Monetary Policy Committee rate decision
  • U.S. chip stocks — the most direct variable for the direction of Samsung Electronics and SK hynix

Prices are based on closing levels; foreign and institutional trading flows are not covered in this article.

Companies in this article 글로벌테크놀로지Samsung ElectronicsSK hynixIndustrial Bank of KoreaARIBIO HoldingsKorea ZincSK InnovationHyundai MotorNAVERKakaoBankDaewoo Engineering & ConstructionGS Engineering & ConstructionHanmi PharmHyosung TNCNongshimDongbang Transport & LogisticsAmorepacificHK inno.NDaewoong Pharma

Investment notice — This article summarizes and interprets public prices, filings and news for information only. It is not a recommendation to buy or sell any security, and the views reflect conditions at the time of writing. All investment decisions and their results are the sole responsibility of the investor.

Sources

Korea Exchange (KRX) · Financial Supervisory Service DART · 메디컬투데이 · 글로벌이코노믹 · 뉴시스경제 · 라이센스뉴스 · 중앙이코노미뉴스 · 아시아경제 · 딜사이트TV · 녹색경제신문 · SBS Biz · 스페셜타임스 · 파이낸셜포스트 · 파이낸셜투데이 · 테크월드 · 아시아투데이 · 불교방송 · 브릿지경제 · 뉴스1 · 전자신문 · 인더스트리뉴스 · 시사저널e · 세계일보 · EBN · 포인트데일리 · 공공뉴스 · FETV · 머니투데이 · 중앙일보 · 디지털타임스 · 스페셜경제 · 이데일리 · 지디넷코리아 · 한스경제 · 데일리한국 · KPI뉴스 · 이뉴스투데이 · 인사이트코리아 · 소셜밸류 · 이슈밸리 · 신아일보 · 더퍼블릭 · 동행미디어 시대 · 매일일보 · 국제뉴스 · 이투데이 · 웹이코노미 · 이코노뉴스 · 공감신문 · 데이터뉴스 · SR타임스 · 이로운넷 · 스마트투데이 · 팍스경제TV

News articles cited or referenced (67, Korean-language originals)

  1. HLB펩, 이원직 신임 사장 영입…글로벌 시장 공략에 속도 — 메디컬투데이
  2. 강남언니, 글로벌 이용자 1000만 명 돌파…K-미용의료 해외 확장 — 글로벌이코노믹
  3. 제바협·식약처, '글로벌 GMP이행기술 교육' 개최 — 뉴시스경제
  4. KB금융, 싱가포르서 스타트업 글로벌 진출 데모데이 개최 — 라이센스뉴스
  5. KIEP, 내년 세계경제 3.2% 성장 전망…AI 호황에 삼성전자·SK하이닉스 수혜와 리스크 공존 — 중앙이코노미뉴스
  6. 신제윤 삼성전자 이사회 의장 "회계사는 경제 핵심 인프라" — 아시아경제
  7. 삼성전자, '갤럭시 AI 클래스' XR 체험 추가 外 — 딜사이트TV
  8. 삼성전자·SK하이닉스, 中 매출 4배 급증…고객·지역 다변화 결실 — 녹색경제신문
  9. 반도체주 '털썩'…하이닉스 7개월만에 110만원 무너져 — SBS Biz
  10. 반도체주 급락, SK하이닉스 7개월 만에 110만원선 붕괴 — 스페셜타임스
  11. 반도체 팹의 '숨은 엔진'…SK하이닉스, IT 조직으로 AX 가속 — 파이낸셜포스트
  12. IBK기업은행, 비수도권에 모험자본 750억원 공급…지역·대학 창업기업 지원 — 파이낸셜투데이
  13. IBK기업은행-한국가스안전공사, 모바일 가상법인카드 도입 ‘맞손’ — 테크월드
  14. IBK기업은행, 비수도권 혁신기업에 750억원 모험자본 공급 — 아시아투데이
  15. IBK기업은행, 가스안전공사에 모바일 가상법인카드 도입 — 불교방송
Show 52 more
  1. 국산 첫 치매 신약 나올까⋯ 거세진 아리바이오 임상 3상 후폭풍 — 브릿지경제
  2. 아리바이오, 알츠하이머 경구약 3상 성공…단독투여군 악화 31% 늦춰 — 뉴스1
  3. 아리바이오 '먹는 치매약' 3상 단독요법 목표 달성…美 허가 여부 주목 — 전자신문
  4. 아리바이오 “먹는 치매약, 단독요법군서 증상 악화 31% 늦춰” — 브릿지경제
  5. 고려아연, 솔라사이클과 합작법인 설립…美태양광 폐패널 재활용 시장서 경쟁력 강화 — 메디컬투데이
  6. 고려아연, 'MS 투자' 美 솔라사이클과 JV 설립…폐태양광 패널 시장 공략 — 인더스트리뉴스
  7. 정부, 해외 광물투자 재개 추진···포스코·고려아연 사업 힘 받나 — 시사저널e
  8. 킬풀/고려아연, ‘마이크로소프트 투자’ 솔라사이클과 합작법인 설립 — 세계일보
  9. [정유·화학 & NOW] SK이노베이션, 우수 AI 스타트업 3곳 발굴 등 — EBN
  10. SK이노베이션, AI 스타트업 3곳 선정…사회문제 해결 기술 사업화 지원 — 포인트데일리
  11. SK이노, AI 스타트업 실증 넘어 사업화 지원 — 공공뉴스
  12. SK이노베이션, AI 임팩트 솔루션 우수 스타트업 3곳 선정 — FETV
  13. 유럽 손실 불어나는데 국내선 파업..현대차 노조 정년연장 압박도 — 머니투데이
  14. “대통령 약속 지켜라”…현대차 노조, ‘65세 정년연장’ 정부·국회 압박 — 중앙일보
  15. 현대차 공장 가동률 ‘뚝’…정의선 공 들인 美·브라질만 ‘풀 가동’ — 디지털타임스
  16. 현대차·모비스, 모셔널에 2547억 출자…무인 로보택시 상용화 속도 — 스페셜경제
  17. 네이버, 전문 크리에이터 콘텐츠 추천 강화...정보 접근성 확대 — 파이낸셜투데이
  18. 美 AI 반도체 규제 강화…네이버 AI 팩토리엔 기회이자 부담 — 이데일리
  19. [반도체의 집③] 'AI인프라 확장' 네이버 VS '안정성 우선' 카카오···엇갈린 플랫폼 AI DC 전략 — 시사저널e
  20. M83 자회사 피앤티링크, 네이버 향 630억원 규모 표준서버 공급 계약 — 지디넷코리아
  21. 카카오뱅크까지 번진 애플페이…수수료 부담에 소비자만 ‘피해’ — 한스경제
  22. [금융단신] 우리은행·경남은행·카카오뱅크·케이뱅크 — 데일리한국
  23. 카카오뱅크, 자립준비청년과 5년 동행…홈커밍데이 개최 — KPI뉴스
  24. 카카오뱅크, 최고 5% 'AI 목표적금' 10만좌 돌파 — 뉴시스경제
  25. 대우건설·져디, 협업···‘신월시영아파트’ 푸르지오 랜드마크 조성 — 이뉴스투데이
  26. 대우건설, 디자인 기업 져디와 신월시영 ‘푸르지오 그랑베르’ 조성 맞손 — 파이낸셜포스트
  27. 이강석 대우건설 대표, 도시정비·해외 LNG 정조준...‘쌍끌이 수주' — 인사이트코리아
  28. 대우건설, 美 설계사 ‘저디’와 신월시영 재건축 협업 — 디지털타임스
  29. 아파트에 라이프·기후·AI를 담다…GS건설이 설계한 미래 '자이' — KPI뉴스
  30. GS건설, 자이 미래 주거 비전 공개…허윤홍 "새로운 기준 먼저 제시할 것" — 소셜밸류
  31. GS건설, 미래 주거 비전 '비욘드 리빙' 선언 — 이슈밸리
  32. [현장] GS건설, 미래 주거 상품 첫선…과제는 '비용·보안' — FETV
  33. 한미약품, 차세대 항암신약 2종 글로벌 임상 1상서 초기 성과 확인 — 신아일보
  34. 한미약품, 차세대 항암신약 2종 글로벌 1상서 초기 항종양 활성 확인 — 더퍼블릭
  35. 한미약품 “항암신약 2종, 1상서 초기 항종양 활성 확인” — 브릿지경제
  36. 1.9조 동맹 릴리와 비만약 승부수 던진 한미약품 — 동행미디어 시대
  37. 효성티앤씨, 사탕수수 기반 '스판덱스'로 유럽 공략 — 매일일보
  38. 효성티앤씨, 사탕수수 원료 '리젠 바이오'로 유럽 시장 공략…베니스 포럼서 의류 첫 공개 — 국제뉴스
  39. 효성티앤씨, 친환경 소재 '리젠 바이오'로 유럽 섬유시장 공략 — 동행미디어 시대
  40. 효성티앤씨, 바이오 스판덱스 '리젠 바이오'로 유럽 공략...베트남 일관 생산체제 앞세워 — 중앙이코노미뉴스
  41. 농심, 볶음너구리 정식 출시…연중 판매 전환 — 파이낸셜포스트
  42. 해외서 성장한 삼양·농심·오뚜기…수익성은 왜 달랐나 — 데일리한국
  43. 농심 '볶음너구리' 한정판서 정규 제품으로…150만 개 조기 완판 전망 — 이투데이
  44. [식음료] 동서식품 캡슐커피 4종·농심 신라면 신제품 출시…풀무원, 미국 급식시장 진출·저탄소 식단·AI 업무 혁신 추진 — 웹이코노미
  45. 삼성전자, '갤럭시 AI 클래스'에 XR 체험 도입 — 이코노뉴스
  46. 효성티앤씨, ‘리젠 바이오’ 앞세워 유럽 섬유시장 공략 — 공감신문
  47. IBK기업은행, 비수도권 지역에 750억 모험자본 공급 — 데이터뉴스
  48. 대신증권, 연 7% 특판 RP 조기 완판…100억 추가 판매 — SR타임스
  49. SK이노베이션, AI 스타트업 3곳 선정…사업화 지원 — 이로운넷
  50. 아모레퍼시픽, 공정거래 자율준수 강화 선포 — 스마트투데이
  51. HK이노엔, '케이캡' 브라질 품목허가 획득...1조 1,000억 원 규모 시장 공략 — 팍스경제TV
  52. 대웅제약, 자가면역 신약 '플로디시티닙' 임상 1상 중간결과 공개 — FETV

DART filings (2)

  1. 아모레퍼시픽 · 기업가치제고계획(자율공시) — DART
  2. 아모레퍼시픽 · 수시공시의무관련사항(공정공시) — DART

Every figure and quoted headline is checked back against these sources before publishing. No price data is used. Copyright in each article belongs to its publisher. How we compile this

Spotted an error? Email ATS@atscorp.kr and we will correct it — see our editorial note.

Questions about today

How much did the KOSPI fall on Nov. 17?
The KOSPI fell 2.59% to 4,968.48 from 5,100.5, and the KOSDAQ fell 2.34% to 650.06.
How did large-cap chip stocks fare?
Following a slump in U.S. chip stocks, Samsung Electronics fell 3.3% and SK hynix 1.96%. SK hynix closed at KRW 1,098,000.
Why did Sorux plunge?
Selling piled into related stocks after AriBio's Phase 3 dementia drug announcement, and Sorux fell 29.86% on volume of 10.38x normal.
What are the next key events?
SFC and Ucast subscriptions run Nov. 18-19, Hana Aerodynamics lists on Nov. 20, and the Bank of Korea makes its rate decision on Nov. 26.